Ruizhen Zhang

Ruizhen Zhang

Auto-generated profile, based on publicly available information

Ruizhen Zhang

School of Pharmacy Shenyang Pharmaceutical University Shenyang Liaoning Province China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Microporous and Mesoporous Materials
Verified
Journal Article
Closed access
RZRuizhen Zhang
Ruizhen Zhang
PZPiaorou Zhao
Piaorou Zhao
LHLina Han
Lina Han
JWJiancheng Wang
Jiancheng Wang
LZLiangfu Zhao
Liangfu Zhao

1 October 2020 in Journal of Solid State Chemistry
Verified
Journal Article
Closed access
JWJie Wang
Jie Wang
RZRuizhen Zhang
Ruizhen Zhang
LHLina Han
Lina Han
JWJiancheng Wang
Jiancheng Wang
LZLiangfu Zhao
Liangfu Zhao

18 May 2022 in Microporous and Mesoporous Materials
Verified
Journal Article
Closed access
RZRuizhen Zhang
Ruizhen Zhang
YWYilin Wang
Yilin Wang
CCChaojing Chai
Chaojing Chai
FLFuling Li
Fuling Li
LHLina Han
Lina Han
LZLiangfu Zhao
Liangfu Zhao

3 May 2024 in Microporous and Mesoporous Materials
Verified
Journal Article
Closed access
RZRuizhen Zhang
Ruizhen Zhang
ZWZhengwei Wen
Zhengwei Wen
CCChaojing Chai
Chaojing Chai
NLNannan Li
Nannan Li
KZKai Zong
Kai Zong
ZLZhikai Li
Zhikai Li

1 May 2012 in Optics Communications
Verified
Journal Article
Closed access
HGHuihuan Guan
Huihuan Guan
PHPeide Han
Peide Han
YLYuping Li
Yuping Li
HZHongwei Zhou
Hongwei Zhou
XZXue Zhang
Xue Zhang
RZRuizhen Zhang
Ruizhen Zhang

21 February 2020 in Chirality
Verified
Journal Article
Open access
PDF file
RRRong Rong
Rong Rong
Xin WangXin Wang
Xin Wang
YDYuhan Dan
Yuhan Dan
RZRuizhen Zhang
Ruizhen Zhang
YZYunli Zhao
Yunli Zhao
RLRaven Lee
Raven Lee
R‐/S‐2‐(2‐hydroxypropanamido)‐5‐trifluoromethyl benzoic acid (R‐/S‐HFBA) is a novel COX inhibitor with remarkable anti‐inflammatory and antiplatelet aggregation activities, but no gastrointestinal toxicity. In our previous study, the different pharmacokinetic profiles of the two enantiomers in rats were observed after administration of R‐HFBA and S‐HFBA. Stereoselective protein binding of the two enantiomers may be a reason for the different pharmacokinetic behaviors. In this study, we developed and validated an UPLC‐MS/MS method for determining stereoselective binding of HFBA enantiomers to rat, dog, and human plasma in vitro. Chromatographic separation was achieved by gradient elution with a flow rate of 0.4 mL/min. MS/MS detection was operated in positive electrospray using multiple reaction monitoring (MRM) mode. The method was proved to be linear over the concentration range of 0.005 to 10 μg/mL with a lower limit of quantification of 0.005 μg/mL. The developed method was successfully employed to the plasma protein binding study of HFBA enantiomers. Equilibrium dialysis method was applied to assess drug‐plasma protein interactions. The results showed that the enantiomers were both extensively bound to three species plasma and protein binding of R‐/S‐HFBA was concentration dependent. R‐HFBA and S‐HFBA showed significant species difference among rat, dog, and human plasma and stereoselective plasma protein binding.